Three-month Insulin Shot Could Offer New Hope to Patients, reveals Kalorama Information

Indian scientists discovered a novel form of insulin that can keep blood glucose levels down for up to three months.
Spread the Word
Listed Under

Type 1 Diabetes


New York City - New York - US

Jan. 21, 2011 - PRLog -- A new product may provide relief for Type 1 insulin-dependent diabetics, one that could have long-term market impact, according to healthcare market research firm Kalorama Information.  Indian scientists discovered a novel form of the hormone that can keep blood glucose levels down for up to three months.

“If developed in a proper delivery mechanism, this could certainly have a long-term impact on the diabetes treatment market, and decrease the stress on patients and caregivers,” said Bruce Carlson, Publisher of Kalorama Information.    

A team of scientists of the National Immunology Institute of India has developed a novel approach to insulin injection called Supramolecular Insulin Assembly-II (SIA-II). SIA-II is a form of the that is used for a sustained treatment of diabetes mellitus Type-I. The studies constitute the first work of its kind where a single administration of SIA-II to animal models of diabetes has been experimentally demonstrated to lower blood glucose levels to normal values for as many as for 120 days.

SIA-II, which is in the form of a prodrug, releases just above basal levels of insulin into the blood in a sustained manner.  A prodrug is a chemical that undergoes changes in the body into a more active material. This just above basal level of insulin is adequate to tackle the increase in blood glucose levels after meals and does not cause severe hypoglycemia in the morning.  

When SIA-II is injected, it forms a depot at the site, from where insulin monomers are released which act on the body's cells to regulate uptake of glucose for months after a single injection. This is in contrast to the existing treatment method in which the patient needs to inject insulin at least twice a day for maintaining glucose levels. SIA-II is unique as it is continuously releasing insulin in the body regularly thereby affording a way to curb increases in glucose levels in between meals. The technique is being seen as one with tremendous therapeutic potential and constitutes a new way of treatment for diabetic patients. Experiments carried out by the group in the laboratory have demonstrated that SIA-II acts as a pure and compact source of insulin and that the reason for its long-term bio-availability is its protection from destruction because of its presentation in a compact form. The research may also give a direction for new therapeutic approaches for various diseases. The hormone insulin is the key regulator of energy and glucose metabolism in the body, besides playing a role in development during growing up years. The fine balance of maintaining the required insulin concentrations in the blood is performed by pancreas. This is according to Kalorama Information’s “The World Market for Diabetes Treatments”, which can be found at:

# # #

About Kalorama Information
Kalorama Information ( supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter:

Please direct all media inquiries to:
Andrea Hiller
Marketing Manager
(212) 807-2673
Email:*** Email Verified
Phone:(212) 807-2673
Tags:Healthcare, Medical, Health, Diabetes, Insulin, Type 1 Diabetes, Patients, Diabetics, Medication, Diabetes Treatment
Industry:Medical, Health, Science
Location:New York City - New York - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Page Updated Last on: Jul 22, 2011
Kalorama Information PRs
Trending News
Top Daily News
Top Weekly News

Like PRLog?
Click to Share